NASDAQ: REVBRevelation Biosciences Inc Stock
$1.19-0.01 (-0.83%)
Updated Mar 20, 2026
REVB Price
$1.19
Fair Value Price
N/A
Market Cap
$4.43M
52 Week Low
$1.14
52 Week High
$44.77
P/E
-0.05x
P/B
0.5x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$8.91M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.31
Operating Cash Flow
-$8M
Beta
1.1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
REVB Overview
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine REVB's potential to beat the market
- REVB doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
REVB
RankedUnranked of 470
RankedUnranked of 470
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $31.84 | A | |
| $15.36 | A | |
| $180.62 | A |
Be the first to know about important REVB news, forecast changes, insider trades & much more!
REVB News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how REVB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
REVB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
REVB is good value based on its book value relative to its share price (0.5x), compared to the US Biotechnology industry average (4.6x)
P/B vs Industry Valuation
REVB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more REVB due diligence checks available for Premium users.
Valuation
REVB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.05x
Industry
27.63x
Market
30.58x
REVB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.5x
Industry
4.6x
REVB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
REVB's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.5M
Profit Margin
0%
REVB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$11.6M
Liabilities
$2.7M
Debt to equity
0.31
REVB's short-term assets ($10.81M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
REVB's short-term assets ($10.81M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
REVB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
REVB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.0M
Investing
$0.0
Financing
-$41.2k
REVB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
REVB vs Biotech Stocks
Revelation Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.